Search
for
Sort by
Research 31–60 of 1000+
- 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles
- IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- Case Report: Multimodal contact immunotherapy in alopecia areata: long-term clinical experience in the JAK inhibitor era
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- 126 Itch of Dermatomyositis treated with topical JAK inhibitor
- Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
- Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
- 681 Inhibition of STAT3, using Oenocarpus bataua vegetable oil, on in vitro model
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Minoxidil Sulfate Regulates JAK / STAT Signalling and Mitochondrial Function in Alopecia Areata
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients